Related Experiment Video
Updated: Mar 8, 2026

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
Antibiotic-Induced Elevations of Plasma Bile Acids in Rats Independent of Bsep Inhibition
Yutai Li1, Michael J Hafey2, Hong Duong1
1Safety Assessment and Laboratory Animal Resources, West Point, Pennsylvania, USA.
Abstract:
Drug-induced liver injury (DILI) is a common toxicity observed in drug development and can lead to withdrawal of approved drugs from the market. To better understand the numerous mechanisms of DILI, recent efforts have focused on transporter inhibition, specifically liver canalicular bile salt export pump (Bsep) as one mechanism of DILI, and on the potential use of plasma bile acids as monitorable mechanism-based biomarkers of Bsep inhibition. To explore alternative mechanisms of bile acid increases in plasma, 6 antibiotic and 2 nonantibiotic drugs unlikely to be Bsep inhibitors were evaluated in rat studies. Surprisingly, all 6 antibiotics demonstrated 2- to 14-fold increases of plasma taurocholic acid (TCA). Also, unconjugated primary bile acids and secondary bile acids (both taurine-conjugated and unconjugated) were decreased in rat plasma after antibiotic treatments, but not with the nonantibiotic drugs. These results suggest alternative mechanisms of bile acids regulation such as attenuation of bacterial deconjugation of bile acids following reduction of gut microflora by antibiotics. Measurements of TCA transport in rat hepatocytes and Bsep-containing membrane vesicles suggest that inhibition of uptake into hepatocytes could also contribute to increases in plasma bile acid concentrations, while excluding inhibition of Bsep as a mechanism. These studies further demonstrate that there are several mechanisms that can lead to conjugated bile acid increases in plasma. By carefully considering the time course and magnitude of changes of individual bile acids relative to any changes seen in transaminases and bilirubin, interpretations and conclusions of the involvement of Bsep inhibition are enabled.
Insights
Antibiotics can increase plasma bile acids through mechanisms other than liver transporter inhibition. These findings highlight alternative pathways for drug-induced liver injury and biomarker interpretation.
Area of Science:
- Pharmacology
- Hepatology
- Drug Development
Background:
- Drug-induced liver injury (DILI) is a significant concern in drug development.
- Liver canalicular bile salt export pump (Bsep) inhibition is a known DILI mechanism.
- Plasma bile acids are potential biomarkers for Bsep inhibition.
Purpose of the Study:
- Investigate alternative mechanisms for increased plasma bile acids.
- Evaluate the effect of antibiotics on bile acid regulation.
- Differentiate Bsep inhibition from other DILI pathways.
Main Methods:
- Administered antibiotics and nonantibiotic drugs to rats.
- Measured plasma bile acid concentrations (TCA, unconjugated, secondary).
- Assessed taurocholic acid transport in hepatocytes and Bsep vesicles.
Main Results:
- Antibiotics significantly increased plasma taurocholic acid (TCA) (2-14 fold).
- Antibiotics decreased unconjugated and secondary bile acids.
- Hepatocyte uptake inhibition, not Bsep inhibition, was implicated in increased plasma bile acids.
Conclusions:
- Antibiotics can elevate plasma bile acids via mechanisms independent of Bsep inhibition, such as reduced gut microflora deconjugation.
- Hepatocyte uptake inhibition may contribute to increased plasma bile acids.
- Distinguishing DILI mechanisms requires analyzing bile acid profiles and liver enzyme changes.
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

